Jazz Hits A High Note With Luvox Resubmissions
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has accepted complete response to “approvable” on Solvay’s Luvox CR, putting U.S. commercialization partner Jazz a step closer to market with the extended-release fluvoxamine formulation.
You may also be interested in...
Jazz Pharmaceuticals’ Luvox CR Gets Feb. 29 Action Date
Company expects to launch the extended-release anti-anxiety medication in the first quarter, after FDA accepts response to “approvable” letter.
Jazz Pharmaceuticals’ Luvox CR Gets Feb. 29 Action Date
Company expects to launch the extended-release anti-anxiety medication in the first quarter, after FDA accepts response to “approvable” letter.
Jazz Pharmaceuticals Gets Second “Approvable” Letter For Once-Daily Luvox
FDA seeks further information on chemistry, manufacturing and controls for Luvox CR NDA.